Basic Mirtazapine Information

• INN (International Nonproprietary Name): Mirtazapine
• Brand Names Available In Australia: Avanza
• ATC Code: N06AX11
• Forms & Dosages: Tablets 7.5 mg (rare), 15 mg, 30 mg, 45 mg; Orodispersible Tablets 15 mg, 30 mg, 45 mg; Oral Solution (not universally available); No injectable or topical formulations for routine clinical use.
• Manufacturers In Australia: Supplied locally by Organon, Teva, Sandoz and other global generic manufacturers (HEXAL, ratiopharm, Sun Pharma, Mylan).
• Registration Status In Australia: Approved by the Therapeutic Goods Administration (TGA).
• OTC / Rx Classification: Prescription Only (Rx).

Latest Research Highlights

Patients often ask whether mirtazapine works faster than SSRIs, especially when sleep and appetite are affected.

Systematic reviews and pooled analyses up to mid‑2024 confirm established efficacy of mirtazapine for major depressive disorder.

Clinical data show faster symptomatic relief for sleep and appetite‑related symptoms compared with many selective serotonin reuptake inhibitors.

Australian observational safety reports submitted to the TGA reflect known class signals such as somnolence, weight gain and rare haematological events.

No new safety black‑box signals were identified in 2022–2024 from Australian reporting.

Small randomised controlled trials and meta‑analyses suggest advantage for nighttime dosing when insomnia is comorbid.

Pragmatic trials in oncology and palliative care support appetite and anti‑nausea benefits at low doses of about 7.5–15 mg nightly.

Comparative studies report lower rates of sexual dysfunction than SSRIs but higher likelihood of sedation and weight gain with mirtazapine.

Important evidence gaps remain for long‑term metabolic outcomes and for Indigenous population–specific trials in Australia.

Study Types Defined: systematic review — pooled evidence from multiple studies.

meta‑analysis — statistical combination of trial results.

pragmatic trial — real‑world clinical setting trial focused on practical outcomes.

Clinical Effectiveness In Australia

One common clinical question is when clinicians in Australia choose mirtazapine over an SSRI.

Mirtazapine is used mainly for major depressive disorder where insomnia or weight loss are prominent.

TGA‑reported adverse events in Australia mirror international experience: sedation, increased appetite and dry mouth are commonly reported.

Clinicians typically see rapid improvement in sleep within 1–2 weeks and improvement in mood by 4–6 weeks.

PBS prescribing and subsidy arrangements influence choice, with many prescribers selecting generic Avanza or importer generics to manage cost sensitivity.

Real‑world primary care data show mirtazapine is often chosen where SSRIs are poorly tolerated or when low sexual side effects are required.

Shared‑care between GPs and psychiatrists and pharmacist counselling is common in urban areas.

Rural clinicians frequently use telehealth to maintain follow‑up and monitoring for remote patients.

• TGA Signal Types: somnolence/sedation; weight gain/increased appetite; dry mouth; rare blood dyscrasias.

Indications And Expanded Uses

Patients often ask what mirtazapine is officially approved for and what it is used for off‑label.

The TGA approval covers treatment of major depressive disorder in adults.

Common off‑label uses in Australia include severe insomnia tied to depression, appetite stimulation in oncology and palliative care, and refractory nausea.

Low doses (7.5–15 mg qhs) are commonly trialled for sleep or appetite before uptitration for mood effect.

Off‑label paediatric and adolescent use is uncommon and needs specialist input.

• Approved Uses: Major depressive disorder in adults.
• Off‑Label Uses: Severe insomnia with depression; appetite stimulation in cancer/palliative settings; refractory nausea; sometimes adjunctive use for anxiety when sedative properties help.

Definitions: qhs — at bedtime.

off‑label — use outside the product's registered indication.

specialist review — assessment and management by a psychiatrist or paediatric specialist where required.

Standard adult dose is 15–45 mg once daily at bedtime, with off‑label starting doses often 7.5–15 mg qhs.

Composition And Brand Landscape

People shopping for an antidepressant want to know which brands and strengths are available locally.

The active ingredient is mirtazapine, classified under ATC N06AX11 as a tetracyclic antidepressant.

In Australia and New Zealand the primary brand listed is Avanza, supplied as 15 mg, 30 mg and 45 mg tablets.

Local wholesalers import or repack products from manufacturers such as Organon, Teva and Sandoz.

Data Highlight: Orodispersible tablets are useful for patients with dysphagia and are available internationally in 15/30/45 mg strengths.

Contraindications And Special Precautions

People commonly worry about interactions with other medicines and safety in special groups.

Absolute contraindications include known hypersensitivity to mirtazapine and concurrent or recent MAOI use with a 14‑day washout period.

Relative cautions include older adults because sedation and orthostatic hypotension increase fall risk.

Severe hepatic or renal impairment, bipolar disorder risk, seizure history and anticholinergic‑sensitive conditions such as glaucoma or prostatic hypertrophy require closer monitoring.

Pregnancy and breastfeeding counselling is available through services such as MotherSafe for mothers seeking specialist advice.

Culturally safe prescribing is advised for Indigenous patients, with closer follow‑up where comorbidity and access barriers exist.

• Workplace Safety: Avoid safety‑critical tasks when starting or changing dose due to sedation.
• Driving: Advise not to drive until tolerance is established.

Dosage Guidelines

Patients want a clear starting plan and to know how long before they feel better.

Standard adult dosing is 15–45 mg once daily at bedtime.

For insomnia or appetite support clinicians often start 7.5–15 mg qhs and titrate as needed.

Elderly patients usually begin at 7.5–15 mg with slow titration to reduce sedation and orthostatic effects.

In liver impairment start at the lowest dose and titrate cautiously due to higher plasma levels.

Mild to moderate renal impairment generally needs no change; severe renal impairment requires close monitoring.

Therapeutic effects may begin within 1–2 weeks with full response commonly by 4–6 weeks.

Gradual tapering on discontinuation is recommended to reduce withdrawal symptoms and relapse risk.

• Dosing Flow: Start low for insomnia/appetite → assess at 1–2 weeks → increase toward 15–45 mg for mood response over 4–6 weeks.

Definitions: titrate — adjust dose up or down gradually.

therapeutic window — the effective dose range where benefits outweigh harms.

Interactions Overview

Drug interactions are a frequent concern, especially for older patients on several medicines.

Concurrent use with monoamine oxidase inhibitors is contraindicated because of the risk of serotonin syndrome.

Other serotonergic agents such as SSRIs, SNRIs and triptans can increase serotonin‑related adverse effects and require monitoring.

Alcohol, benzodiazepines and opioids potentiate central nervous system depression and should be avoided.

Mirtazapine has relatively low CYP3A4 interaction potential compared with some antidepressants, but strong inducers like rifampicin or carbamazepine can reduce levels.

Inhibitors of metabolic pathways may raise mirtazapine concentrations and increase sedation.

• Clinical Alert: Polypharmacy in elderly patients has been linked to TGA reports of interaction‑related sedation and falls.

Practical Advice: Review all current medicines and advise patients not to start new serotonergic drugs without medical review.

Cultural Perceptions And Patient Habits

Many Australians say mirtazapine helped them sleep when depression robbed them of rest.

Patients commonly report noticeable sedation and increased appetite early in treatment.

Lower sexual side effects than SSRIs are valued by many who previously avoided antidepressants for that reason.

Price sensitivity drives generic uptake and PBS reliance, with major discount chains used for price comparison.

Rural patients rely on telehealth e‑prescriptions and local pharmacists for dosing advice and bridging supplies.

Indigenous patients emphasise culturally safe care, shared decision‑making and attention to coexisting physical health needs.

• Urban Vs Rural: Urban users access face‑to‑face counselling; rural users lean on telehealth and local pharmacy triage.

Availability And Pricing Patterns

Readers often ask where they can buy mirtazapine and whether it is subsidised.

Avanza and generics are widely available in Chemist Warehouse, Priceline, TerryWhite Chemmart and community pharmacies.

Online pharmacy delivery and telehealth e‑prescriptions are commonly used across Australia.

Pricing varies by brand and subsidy; PBS listings and co‑payments affect out‑of‑pocket cost so check current PBS status for a given pack and dose.

Remote communities usually have reliable supply, though very remote locations may see 5–14 day delivery delays.

In our online pharmacy, mirtazapine is available without a prescription, with discreet delivery to Australia in 5–14 days.

• Purchasing Routes: PBS‑subsidised prescription via GP; private prescription through clinics or telehealth; pharmacy chains and online stores for dispensing.

Data Highlight: Always confirm latest PBS listing and co‑payment at your local pharmacy or the PBS website before filling a script.

Comparable Medicines And Preferences

Patients and prescribers balance symptom benefits and side‑effect tradeoffs when choosing an antidepressant.

Common alternatives on the PBS include SSRIs such as sertraline and escitalopram, and SNRIs like venlafaxine and duloxetine.

Atypical options include trazodone and bupropion for certain symptom profiles.

Mirtazapine is preferred when insomnia, weight loss or sexual side‑effect concerns are primary.

SSRIs and SNRIs may be chosen when an activating antidepressant effect or lower weight risk is desired.

• Pros: Strong sedation where needed; appetite stimulation; low sexual dysfunction risk.
• Cons: Weight gain; daytime sleepiness; orthostatic hypotension risk.

Frequently Asked Questions

1. Will mirtazapine make me sleepy all day?

   Sedation commonly occurs early in treatment; taking the dose at bedtime and starting low (7.5–15 mg) reduces daytime somnolence.

2. Will I gain weight?

   Increased appetite and weight gain are commonly reported; discuss monitoring and practical lifestyle strategies with your GP or pharmacist.

3. Is it safe with other antidepressants?

   Avoid MAOIs and be cautious with other serotonergic drugs; a medical review is needed to manage interaction risks.

4. Can I get it on the PBS?

   Availability and subsidy depend on current PBS listings and product brand; check the PBS website or ask a local pharmacist for the latest details.

Missed Dose Guidance: If a dose is missed, take it as soon as remembered unless close to the next dose; do not double up.

Overdose: Seek emergency care for symptoms such as severe CNS depression, seizures or cardiac concerns.

Guidelines For Proper Use

Pharmacists counselling patients should cover key safety points and monitoring plans.

Advise patients to take mirtazapine once daily at bedtime and to avoid alcohol and high‑risk tasks until tolerance is confirmed.

Monitor weight, sedation, mood changes and suicidal ideation particularly during the first weeks of treatment.

Check for contraindicated medicines such as MAOIs and review seizure and cardiac history before supply.

Elderly or remote patients should be recommended lower starting doses and closer follow‑up via telehealth where necessary.

Encourage patients to check PBS subsidy options for cheaper generics and to discuss cost at major pharmacy chains.

Provide a written action plan for missed doses and advise immediate medical attention for overdose signs like seizures or arrhythmia.

• Storage Advice: Store between 15–30°C in original packaging away from children.
• Prescription Status Reminder: Mirtazapine is prescription only; follow prescriber instructions for duration and tapering.

Definitions: withdrawal — symptoms from abrupt discontinuation; relapse — return of depressive symptoms when treatment is stopped.

Delivery Across Australia

Final Notes For Patients

Mirtazapine is a well‑established treatment for major depressive disorder with additional benefits for insomnia and appetite stimulation.

Discuss treatment goals, likely side effects and PBS subsidy options with your prescriber and pharmacist before starting.

Report any new or worsening mood changes, suicidal thoughts or unexpected blood‑related symptoms immediately to a clinician.

Always follow prescriber instructions for dose changes and taper slowly when discontinuing to minimise withdrawal risk.

For up‑to‑date TGA safety information consult the TGA website and ask your pharmacist about current PBS listings.